Abeona Therapeutics INC Form 4 insider transactions

Director Mark Alvino of Abeona Therapeutics sold 8,000 shares of common stock on May 16, 2025, at an average price of $5.68.

Abeona Therapeutics CEO Vishwas Seshadri sold 25,000 shares of common stock on March 31, 2025, at an average price of $4.78, according to a Form 4 filing with the SEC.

Chief Financial Officer of Abeona Therapeutics, Joseph Vazzano, reports disposing of 685 shares of common stock to cover tax obligations upon vesting of restricted stock.

Brendan O'Malley, SVP and General Counsel of Abeona Therapeutics, disposed of 181 shares of common stock on March 3, 2025, to cover tax withholding obligations upon vesting of restricted stock.

Director Faith L. Charles acquired 36,101 shares of Abeona Therapeutics stock through vesting of restricted stock on January 31, 2025.

Abeona Therapeutics director Michael Amoroso acquired 36,101 shares of common stock through vesting of restricted stock.

Director Donald A. Wuchterl acquired 36,101 shares of Abeona Therapeutics stock through vesting of restricted stock on January 31, 2025.

Christine Silverstein, a director at Abeona Therapeutics, acquired 36,101 shares of common stock through vesting of restricted stock.

Abeona Therapeutics director Eric Crombez acquired 36,101 shares of common stock through vesting on January 31, 2025.

Director Bernhardt G Zeiher acquired 36,101 shares of Abeona Therapeutics common stock through vesting of restricted stock.

Director Leila Alland acquired 36,101 shares of Abeona Therapeutics stock through vesting on January 31, 2025.

Director Mark Alvino of Abeona Therapeutics acquired 36,101 shares of common stock through vesting of restricted stock.

Director Mark Alvino of Abeona Therapeutics sold 4,000 shares of common stock at an average price of $5.38 on January 29, 2025.

Abeona Therapeutics' Senior Vice President and General Counsel, Brendan M. O'Malley, was granted 115,607 shares of restricted stock.

Abeona Therapeutics' Chief Financial Officer, Joseph Walter Vazzano, acquired 144,509 shares of restricted stock on January 21, 2025.

Abeona Therapeutics CEO Vishwas Seshadri acquired 476,435 shares of restricted stock on January 21, 2025, which will vest over three years.

Director Mark Alvino sold 4,000 shares of Abeona Therapeutics Inc. common stock at an average price of $5.10 on January 21, 2025.

Abeona Therapeutics CEO Vishwas Seshadri reports disposition of shares to cover tax obligations upon vesting of restricted stock.

Brendan O'Malley, SVP, General Counsel of Abeona Therapeutics, reports disposition of shares to cover tax obligations upon vesting of restricted stock.

Abeona Therapeutics' CEO, Vishwas Seshadri, disposed of shares to cover tax obligations upon vesting of restricted stock.

Joseph Vazzano, CFO of Abeona Therapeutics, disposed of 6,388 shares of common stock on September 28, 2024, to satisfy tax withholding obligations upon the vesting of restricted stock.

Brendan M. O'Malley, SVP and General Counsel of Abeona Therapeutics, disposed of 496 shares of common stock to cover tax obligations upon vesting of restricted stock on September 20, 2024.

Director Donald A. Wuchterl acquired 11,797 shares of Abeona Therapeutics common stock on August 26, 2024, as part of the company's annual board grant.

Christine Berni Silverstein, a director of Abeona Therapeutics, acquired 11,797 shares of common stock as part of the company's annual grant to the board of directors.

Director Faith L. Charles reports acquisition of 11,797 shares of Abeona Therapeutics common stock as part of the 2024 annual grant to the board of directors.

Director Michael Amoroso reports acquisition of Abeona Therapeutics shares as part of the company's annual board grant.

Director Mark Alvino acquired 11,797 shares of Abeona Therapeutics common stock as part of the 2024 annual grant to the board of directors.

Director Leila Alland acquired 11,797 shares of Abeona Therapeutics common stock as part of the remainder of the 2024 annual grant to the board of directors.

Director Eric Crombez acquired 11,044 shares of Abeona Therapeutics common stock on August 13, 2024.

Bernhardt G. Zeiher, a director of Abeona Therapeutics Inc., acquired 11,044 shares of common stock on August 13, 2024.